Nikolaos A. Papanikolaou

Prof. Nikolaos A. Papanikolaou

Biological Chemistry, Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SIStavros Iliadis
Stavros Iliadis
NPNikolaos A. Papanikolaou
Nikolaos A. Papanikolaou
Reactive oxygen species (ROS) are produced during cellular metabolism and in response to environmental stress. While low levels of ROS play essential physiological roles, excess ROS can damage cellular components, leading to cell death or transformation. ROS can also regulate protein interactions in cancer cells, thereby affecting processes such as cell growth, migration, and angiogenesis. Dysregulated interactions occur via various mechanisms, including amino acid modifications, conformational changes, and alterations in complex stability. Understanding ROS-mediated changes in protein interactions is crucial for targeted cancer therapies. In this review, we examine the role that ROS mechanisms in regulating pathways through protein–protein interactions.

20 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SIStavros Iliadis
Stavros Iliadis
NPNikolaos A. Papanikolaou
Nikolaos A. Papanikolaou
Reactive oxygen species (ROS) are produced during cellular metabolism and in response to environmental stress. While low levels of ROS play essential physiological roles, excess ROS can damage cellular components, leading to cell death or transformation. ROS can also regulate protein interactions in cancer cells, thereby affecting processes such as cell growth, migration, and angiogenesis. Dysregulated interactions occur via various mechanisms, including amino acid modifications, conformational changes, and alterations in complex stability. Understanding ROS-mediated changes in protein interactions is crucial for targeted cancer therapies. In this review, we examine the role that ROS mechanisms in regulating pathways through protein-protein interactions.

22 April 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
NPNikolaos A. Papanikolaou
Nikolaos A. Papanikolaou
MKMaria Kakavoulia
Maria Kakavoulia
CLChristos Ladias
Christos Ladias
APAthanasios G. Papavassiliou
Athanasios G. Papavassiliou

23 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DKDespina Komninou
Despina Komninou
NPNikolaos A. Papanikolaou
Nikolaos A. Papanikolaou
Metabolites are commonly interpreted through abundance, pathway flux, pathway assignment, or thermodynamic feasibility. These measurements are essential, but they do not by themselves explain how the same molecule is assigned to different biochemical functions. Here we develop the partition theory of metabolite function to describe this allocation explicitly. We define the partition vector, π(τ), for a metabolite M as the central variable of the framework. Its components represent the time-integrated fractions of M captured by competing reaction, pathway, or compartmental sinks during a biologically relevant decision window τ. Because π(τ) is normalized, it describes how metabolite utilization is distributed among competing fates, rather than how much metabolite is present or how much total flux passes through a pathway. This framework leads naturally to partition entropy as a measure of metabolite-fate ambiguity, to partition-control relations that distinguish flux-changing from fate-redirecting perturbations, to cross-metabolite coupling through shared sinks, and to history dependence when downstream marks or assembly states retain the record of metabolite use. The framework does not replace metabolic control analysis, flux balance analysis, or thermodynamic flux analysis. Rather, it reorganizes quantities that these approaches already help define into a metabolite-centered state variable, the fraction of utilization captured by each competing sink. A literature-constrained acetyl-CoA example illustrates how sink sensitivity can be evaluated without inventing a universal empirical acetyl-CoA partition vector.

30 October 2023 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
CLChristos Ladias
Christos Ladias
PPPavlos Papakotoulas
Pavlos Papakotoulas
MPMaria Papaioannou
Maria Papaioannou
NPNikolaos A. Papanikolaou
Nikolaos A. Papanikolaou
Alternative protein-protein interactions (PPIs) arising from mutations or post-translational modifications (PTMs), termed phenotypic switching (PS), are critical for the transmission of alternative pathogenic signals and are particularly significant in cancer. In recent years, PPIs have emerged as promising targets for rational drug design, primarily because their high specificity facilitates targeting of disease-related signaling pathways. However, obstacles exist at the molecular level that arise from the properties of the interaction interfaces and the propensity of small molecule drugs to interact with more than one cleft surface. The difficulty in identifying small molecules that act as activators or inhibitors to counteract the biological effects of mutations raises issues that have not been encountered before. For example, small molecules can bind tightly but may not act as drugs or bind to multiple sites (interaction promiscuity). Another reason is the absence of significant clefts on protein surfaces; if a pocket is present, it may be too small, or its geometry may prevent binding. PS, which arises from oncogenic (alternative) signaling, causes drug resistance and forms the basis for the systemic robustness of tumors. In this review, the properties of PPI interfaces relevant to the design and development of targeting drugs are examined. In addition, the interactions between three tyrosine kinase inhibitors (TKIs) employed as drugs are discussed. Finally, potential novel targets of one of these drugs were identified in silico.

30 March 2018 in Cancer Studies
Verified
Journal Article
Open access
NKNikolaos I. Kalosidis
Nikolaos I. Kalosidis
AMAegli Mantsou
Aegli Mantsou
NPNikolaos A. Papanikolaou
Nikolaos A. Papanikolaou
Understanding the biochemical mechanisms of tumorigenesis remains a challenge. This is due to the hierarchical organization of cells and tissues which complicates the linking of genomic events, such as mutations, to phenotypes. Biomolecules function in complexes and in networks whose properties depend on signaling, mutation status, location and association with other proteins. We postulate that a key driver of phenotypic switching in tumor development is the formation of alternative complexes by oncogenic proteins, via network shortest paths, which control rate-limiting steps. Rate-limiting steps are the only ones that can increase pathway activity and this requires the application of complex systems dynamics analysis. Oncogene addiction-driven diversion of oncogenic signaling in mutated/overexpressed kinases in melanoma tumorigenic pathways is used in support of our proposal.